30 Participants Needed

Hyperfine MRI for Detecting Brain Injury in Pediatric ECMO Patients

MS
Overseen ByMaura Sien, MSML, CCRC
Age: < 18
Sex: Any
Trial Phase: Academic
Sponsor: Children's Mercy Hospital Kansas City
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 7 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether participants need to stop taking their current medications.

What data supports the effectiveness of the Hyperfine, Swoop Portable MR Imaging System, Swoop System treatment for detecting brain injury in pediatric ECMO patients?

Research shows that MRI is a sensitive and noninvasive method for detecting brain changes and complications during ECMO, and portable MRI systems have been successfully used at the bedside in pediatric patients, making it a promising tool for early diagnosis and treatment guidance.12345

Is the Hyperfine MRI system safe for use in humans?

Research shows that the Hyperfine MRI system, also known as the Swoop Portable MR Imaging System, is safe for use in both adults and children, including those in intensive care settings. It has been used safely in patients on ECMO (a machine that helps with heart and lung function) and with other medical devices, without any adverse effects from the MRI itself.15678

How is the Hyperfine MRI treatment different from other treatments for detecting brain injury in pediatric ECMO patients?

The Hyperfine MRI, also known as the Swoop Portable MR Imaging System, is unique because it is a portable MRI system that can be used at the bedside, making it easier to perform brain scans in critical care settings like the neonatal intensive care unit (NICU). This is different from traditional MRI machines, which are large and require patients to be transported to a separate imaging department.123910

What is the purpose of this trial?

The primary objective is to characterize the prevalence and type of ABI following cannulation for pediatric patients who require ECMO support. The secondary objective is to describe the time course and rates of ABI using ultralow-field bedside MRI relative to both duration of ECMO support and clinical imaging obtained in routine care of pediatric ECMO patients.

Research Team

JW

Jessica Wallisch, MD

Principal Investigator

Children's Mercy Kansas City

Eligibility Criteria

This trial is for pediatric patients aged 0-17 years who are receiving ECMO support due to conditions like brain injury from lack of oxygen, stroke, or trauma. They must be in the Pediatric Intensive Care Unit, Cardiac Intensive Care Unit, or Neonatal Intensive Care Unit.

Inclusion Criteria

Undergoing venovenous or venoarterial ECMO
My child is in the ICU, CICU, or NICU.
I am 17 years old or younger.

Exclusion Criteria

I have worked as a welder, metal worker, or have had a metal injury.
Active implants such as pacemaker, implanted defibrillator, implanted insulin pump, deep brain stimulator, vagus nerve stimulator, cochlear implant, programmable shunt
Metal-containing tattoos or permanent make-up on head or neck
See 5 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Perform bedside MRI in pediatric ECMO patients within 24 hours of cannulation and weekly until decannulation

2 weeks
Multiple visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Hyperfine
Trial Overview The study aims to use a portable MRI device called Hyperfine to detect acute brain injuries (ABI) in children on ECMO support. It will track how often and when these injuries occur during treatment compared with routine care imaging.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Portable MRI ArmExperimental Treatment1 Intervention
All subjects enrolled will be assigned to Arm 1

Hyperfine is already approved in United States, European Union, Canada, United Kingdom for the following indications:

🇺🇸
Approved in United States as Swoop Portable MR Imaging System for:
  • Brain imaging
🇪🇺
Approved in European Union as Swoop Portable MR Imaging System for:
  • Brain imaging
🇨🇦
Approved in Canada as Swoop Portable MR Imaging System for:
  • Brain imaging
🇬🇧
Approved in United Kingdom as Swoop Portable MR Imaging System for:
  • Brain imaging

Find a Clinic Near You

Who Is Running the Clinical Trial?

Children's Mercy Hospital Kansas City

Lead Sponsor

Trials
261
Recruited
941,000+

Findings from Research

This study is the first to demonstrate that MRI can be safely performed during extracorporeal membrane oxygenation (ECMO) without adversely affecting the ECMO system, as shown in a healthy pig model.
MRI provides high-quality anatomical and functional images of the brain and thoracic vessels, suggesting its potential for early diagnosis of cerebral complications and for research on brain perfusion during ECMO.
MRI of the brain and thorax during extracorporeal membrane oxygenation: preliminary report from a pig model.Lidegran, MK., Frenckner, BP., Mosskin, M., et al.[2016]
In a study of 50 neonates who underwent MRI after ECMO, MRI detected abnormalities in 62% of cases, significantly more than the 24% detected by head ultrasound (HUS), indicating that MRI may be a more effective imaging method post-ECMO.
Despite the higher detection rate of abnormalities with MRI, neither MRI nor HUS findings were linked to early neurodevelopmental outcomes, with the need for supplemental tube feeds at discharge being the strongest predictor of neurological impairment.
Utility of neuroradiographic imaging in predicting outcomes after neonatal extracorporeal membrane oxygenation.Rollins, MD., Yoder, BA., Moore, KR., et al.[2012]
A study involving 60 infants in a neonatal intensive care unit (NICU) demonstrated that point-of-care 1-Tesla MRI can effectively identify significant intracranial pathologies, such as ischemic lesions and microhemorrhages, which are crucial for timely medical intervention.
While the 1-Tesla MRI had limitations compared to higher-field strength MRIs (like 3-Tesla), it still provided valuable diagnostic information that was not visible on transcranial ultrasound, highlighting its potential utility in NICU settings.
A 1-Tesla MRI system for dedicated brain imaging in the neonatal intensive care unit.Berson, ER., Mozayan, A., Peterec, S., et al.[2023]

References

MRI of the brain and thorax during extracorporeal membrane oxygenation: preliminary report from a pig model. [2016]
Utility of neuroradiographic imaging in predicting outcomes after neonatal extracorporeal membrane oxygenation. [2012]
A 1-Tesla MRI system for dedicated brain imaging in the neonatal intensive care unit. [2023]
Patterns of Brain Injury in Newborns Treated with Extracorporeal Membrane Oxygenation. [2021]
Feasibility of bedside portable MRI in neonates and children during ECLS. [2023]
Feasibility of and experience using a portable MRI scanner in the neonatal intensive care unit. [2022]
Safety of Bedside Portable Low-Field Brain MRI in ECMO Patients Supported on Intra-Aortic Balloon Pump. [2023]
Lung structure and function on MRI in preterm born school children with and without BPD: A feasibility study. [2023]
Risk Factors for Brain Injury in Newborns Treated with Extracorporeal Membrane Oxygenation. [2022]
10.United Statespubmed.ncbi.nlm.nih.gov
Neurodevelopmental Outcomes in Extracorporeal Membrane Oxygenation Patients: A Pilot Study. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security